CLOs on the Move

Allarity Therapeutics

www.allarity.com

 
Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Cambridge, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.allarity.com
  • 210 Broadway # 201
    Cambridge, MA USA 02139
  • Phone: 401.426.4664

Executives

Name Title Contact Details

Similar Companies

Avecia Biotechnology

Avecia Biotechnology is a Milford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gnosko Bio

Gnosko Bio is a medical and laboratory supply company based in Philadelphia, PA that provides real-time inventory management automation solutions for the biotech industry.

Monticello Drug Companies

Monticello Drug Companies is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ohm Laboratories

Ohm Laboratories is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.